UA90496C2 - 18-метил-19-нор-17-прегн-4-эн-21,17-карболактоны, а также лекарственный препарат, который их содержит - Google Patents

18-метил-19-нор-17-прегн-4-эн-21,17-карболактоны, а также лекарственный препарат, который их содержит

Info

Publication number
UA90496C2
UA90496C2 UAA200708684A UAA200708684A UA90496C2 UA 90496 C2 UA90496 C2 UA 90496C2 UA A200708684 A UAA200708684 A UA A200708684A UA A200708684 A UAA200708684 A UA A200708684A UA 90496 C2 UA90496 C2 UA 90496C2
Authority
UA
Ukraine
Prior art keywords
methyl
carbolactones
pregn
pharmaceutical preparations
branched
Prior art date
Application number
UAA200708684A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рольф Больманн
Дитер Биттлер
Херманн Кюнцер
Петер Эсперлинг
Ханс-Петер Мун
Карл-Хайнрих Фритцемайер
Ульрике Фурманн
Катя Прелле
Борден, (раньше Курц) Штеффен
Original Assignee
Байер Шеринг Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36087369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA90496(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Шеринг Фарма Акциенгезельшафт filed Critical Байер Шеринг Фарма Акциенгезельшафт
Publication of UA90496C2 publication Critical patent/UA90496C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение касается новых 18-метил-19-нор-17-прегн-4-эн-21,17-карболактонов общей формулы И, Формула Ив которойZ представляет собой атом кислорода, два атома водорода, группировка =NOR или =NNHSOR,причем R означает атом водорода или алкильную группу с прямой или разветвленной цепью, которая содержит от 1 до 4 или от 3 до 4 атомов углерода,Rозначает атом водорода, атом галогена, метильную или трифторметильную группу,Rи/или Rмогут находиться в α- или β-положении и независимо один от другого означают алкильную группу с прямой или разветвленной цепью, которая содержит от 1 до 4 ил
UAA200708684A 2004-12-30 2005-12-30 18-метил-19-нор-17-прегн-4-эн-21,17-карболактоны, а также лекарственный препарат, который их содержит UA90496C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004063864A DE102004063864A1 (de) 2004-12-30 2004-12-30 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
UA90496C2 true UA90496C2 (ru) 2010-05-11

Family

ID=36087369

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200708684A UA90496C2 (ru) 2004-12-30 2005-12-30 18-метил-19-нор-17-прегн-4-эн-21,17-карболактоны, а также лекарственный препарат, который их содержит

Country Status (33)

Country Link
US (1) US20090029953A1 (ru)
EP (1) EP1831240B8 (ru)
JP (1) JP5043681B2 (ru)
KR (1) KR20070093443A (ru)
CN (1) CN101128476B (ru)
AR (1) AR052657A1 (ru)
AU (1) AU2005324055A1 (ru)
BR (1) BRPI0518533A2 (ru)
CA (1) CA2594171C (ru)
CR (1) CR9223A (ru)
CY (1) CY1109498T1 (ru)
DE (2) DE102004063864A1 (ru)
DK (1) DK1831240T3 (ru)
EA (1) EA014325B1 (ru)
ES (1) ES2331322T3 (ru)
GT (1) GT200500394A (ru)
HK (1) HK1112627A1 (ru)
IL (1) IL184288A (ru)
MX (1) MX2007008074A (ru)
MY (1) MY145904A (ru)
NO (1) NO20073257L (ru)
NZ (1) NZ556150A (ru)
PA (1) PA8658401A1 (ru)
PE (2) PE20060853A1 (ru)
PL (1) PL1831240T3 (ru)
PT (1) PT1831240E (ru)
RS (1) RS51128B (ru)
SI (1) SI1831240T1 (ru)
TW (1) TW200635942A (ru)
UA (1) UA90496C2 (ru)
UY (1) UY29320A1 (ru)
WO (1) WO2006072467A1 (ru)
ZA (1) ZA200706254B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027636A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063495A1 (de) * 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063500A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063501A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063499A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063503A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
WO2010068500A2 (en) * 2008-11-25 2010-06-17 Evestra, Inc. PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a -YL) PROPIONIC ACID g-LACTONES
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2010066349A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959322A (en) * 1960-09-22 1976-05-25 Herchel Smith Synthesis of 13-alkyl-gon-4-ones
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone

Also Published As

Publication number Publication date
GT200500394A (es) 2006-08-01
PT1831240E (pt) 2009-10-22
IL184288A0 (en) 2007-10-31
KR20070093443A (ko) 2007-09-18
MY145904A (en) 2012-05-15
NZ556150A (en) 2011-02-25
CY1109498T1 (el) 2014-08-13
JP5043681B2 (ja) 2012-10-10
WO2006072467A1 (de) 2006-07-13
CN101128476B (zh) 2011-02-09
CA2594171A1 (en) 2006-07-13
CA2594171C (en) 2012-10-16
UY29320A1 (es) 2006-07-31
JP2008526709A (ja) 2008-07-24
EA014325B1 (ru) 2010-10-29
PE20100736A1 (es) 2010-12-03
NO20073257L (no) 2007-08-29
EP1831240B1 (de) 2009-07-15
DE102004063864A1 (de) 2006-07-13
DK1831240T3 (da) 2009-11-23
BRPI0518533A2 (pt) 2008-11-25
AU2005324055A1 (en) 2006-07-13
US20090029953A1 (en) 2009-01-29
TW200635942A (en) 2006-10-16
AR052657A1 (es) 2007-03-28
EP1831240A1 (de) 2007-09-12
PL1831240T3 (pl) 2010-01-29
ZA200706254B (en) 2008-12-31
PA8658401A1 (es) 2006-08-03
HK1112627A1 (ru) 2008-09-12
CR9223A (es) 2007-11-23
PE20060853A1 (es) 2006-09-15
EP1831240B8 (de) 2010-02-17
MX2007008074A (es) 2008-03-10
DE502005007723D1 (de) 2009-08-27
EA200701239A1 (ru) 2007-12-28
IL184288A (en) 2011-06-30
SI1831240T1 (sl) 2009-12-31
ES2331322T3 (es) 2009-12-29
RS51128B (sr) 2010-10-31
CN101128476A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
UA90496C2 (ru) 18-метил-19-нор-17-прегн-4-эн-21,17-карболактоны, а также лекарственный препарат, который их содержит
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
IL173161A0 (en) Pyridazinyl-piperazines and their use as histamine h3 receptor ligands
WO2004026248A3 (en) Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2005046603A3 (en) Pyridine compounds
HUP0202400A2 (hu) Prosztaglandinszármazékot tartalmazó készítmény külső elválasztási rendellenességek kezelésére
GB0112348D0 (en) Compounds
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
NZ527867A (en) Oral pharmaceutical composition of cefpodoxime proxetil
WO2003024928A3 (en) Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
IL147149A0 (en) Novel diphenyl-piperidine derivate
PL1831239T3 (pl) Sposób wytwarzania gamma-laktonu kwasu 17-hydroksy-6 beta, 7 beta,15 beta, 16 beta-bismetyleno-17 alpha-pregn-4-en-3-ono-21-karboksylowego i związki pośrednie kluczowe dla tego sposobu
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
GB0322510D0 (en) Novel compounds
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
EP1617806A4 (en) SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS
SE0303480D0 (sv) Benzofuranes
MXPA03005374A (es) Carbazoles antitumorales.
TW200510354A (en) Benzoxazinone-derived sulphonamide compounds, their preparation and use as medicaments
HK1085744A1 (en) Steroid compounds with anti-tumor activity
ZA200205362B (en) Unsaturated 14, 15-cyclopropane-androstanes, a method for their production and pharmaceutical compositions containing these compounds.
ECSP992934A (es) Procedimiento mejorado para la preparacion de derivados de norbenzomorfano, valiosos farmaceuticamente